Tripep raises SEK 24 million through a new issue

The Board of Directors of Tripep has resolved to make a new issue of 2 million shares at a subscription price of 13 SEK per share. The share issue is directed to a small group of investors, mainly small institutions and private investors. Tripep raises SEK 26 million through the new issue prior to deductions for issue costs, which are estimated to approximately SEK 2 million. The new issue was resolved based on the authorization by the extraordinary general meeting on 9 June 2005. ”The capital contribution generated by the warrants and this new issue secures the financial position of the company until the end of 2006. We now have the resources in place for the continued development of alphaHGA and for the preparations needed to take ChronVac-C® to the clinical phase at the end of the year”, says Jan Nilsson, CEO of Tripep. Remium is financial advisor to Tripep in the new issue. Remium has borrowed two million existing shares from Tripep’s principal shareholder Dormant Properties AB in order to enable immediate delivery of shares against payment. This will take place today. Following registration of the new issue and shares issued through recent exercise of Tripep’s listed warrants, the number of outstanding shares in Tripep will amount to 23,566,068. The two million shares represent, together with other shares issued by Tripep during the last twelve months, more than ten per cent of the number of shares in Tripep already admitted to trading on the Stockholm Stock Exchange. Tripep will therefore prepare a prospectus in order to have the two million newly issued shares admitted to trading on the Stockholm Stock Exchange. For more information, please contact: Rolf L. Nordström, Chairman, Tripep AB Tel: +44 20 7495 1480, mobile phone: +44 7776 137 400 E-mail: rolf.l.nordstrom@btinternet.com Jan Nilsson, CEO, Tripep AB Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Subscribe

Documents & Links